Forget Antibodies. Use Aptamers!™ Forget Antibodies. Use Aptamers!™
R&D Inquiry Quote
Contact Us

Apta-Index™: Endothelial Integrin Alpha-V Beta-3 (Clone 17.16) (ID# 222)

Back to Search Results

Endothelial Integrin Alpha-V Beta-3 (Clone 17.16) (ID# 222)

Endothelial Integrin Alpha-V Beta-3 (Clone 17.16)
* The secondary structure may not be accurate because of MFOLD limitations on chemistries other than RNA/DNA.
RNA Alpha-V Beta-3 Protein N/A nM (reported value) Washed with PBS and 0.9 mM CaCl2, 0.5 mM MgCl2, 2.67 mM KCl, 1.47 mM KH2PO4, 135 mM NaCl, and 8 mM Na2. N/A If the oligo is a known aptamer sequence: For binding studies, perform a refolding program to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding. See also PF377 P-Selectin Aptamer for an aptamer that also decreases sickled RBC binding to HUVECs.
5'-rUprUprCprAprAprCprGprCprUprGprUprGprAprAprGprGprGprCprUprUprAprUprAprCprGprAprGprCprGprGprAprUprUprAprCprCprCp-3'
37 11855.18 g/mole 364200.00 L/(mole·cm) 51.35% 2.75 32.55

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Brunette et al. "RNA Aptamer Therapy for Vaso-Occlusion in Sickle Cell Disease." Nucleic Acids Therapeutics, 21(2011): 275-283. Mi et al. "Targeted inhibition of avß3 integrin with an RNA aptamer impairs endothelial cell growth and survival." Biochemical and Biophysical Research Communications, 338(2005): 956-963.

Have your aptamer oligo synthesized by one of our AFFILIATES

Community Feedback

Forget Antibodies. Use Aptamers!™ Forget Antibodies. Use Aptamers!™